Also, in scope treatments targeting ‘fast-growing’ NTMs of the M.abscessus complex esp. We are seeking project proposals which have the potential to address the TPPs identified, in particular:Īntimicrobials focused on Pseudomonas aeruginosa infections as 1) a maintenance therapy to suppress chronic respiratory infection or 2) treatment of acute pulmonary exacerbations linked to Pseudomonas aeruginosa infection.Īntimicrobials focused on Mycobacterium abscessus infections as 1) a maintenance therapy to suppress chronic respiratory infection or 2) treatment of acute pulmonary exacerbations linked to M.abscessus infection, or 3) eradication treatment. Projects will be milestone-driven and expected to last up to 2 years, with total project costs of up to £500,000 GBP. Our funding is open to researchers in academia and small and medium enterprises (SMEs) worldwide. Our intention is not just to fund but to add additional collaborative support and advice to enable the best chances of success for the project. Unlike typical grant funding, we offer a truly collaborative approach to project development and delivery. This £3 million GBP fund (provided by LifeArc) will support up to 5 early-stage drug discovery projects that seek to develop new therapeutics to treat lung infections in CF. The first funding call associated with this programme is entitled: New Therapeutics to treat lung infections in CF. In 2023, we are launching a new programme, the Collaborative Discovery Programme. We are looking to help create and advance an exciting and diverse pipeline of preclinical phase projects aimed at treating lung infections in people with Cystic Fibrosis.
0 kommentar(er)
